Kienle Breast Cancer.pdf - AnthroMed Library

Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL (Continued)
Breast,
others
Breast, ovary,
lung
All stages Iscador (39) Selfregulation
questionnair
e
T 1–4 , N 0–3 , M 0–1
(score 1–6)
None (39) 3.85 3.62
Chemothera
py I , Helixor A
(115)
Chemothera
py I , Lentinan
(109)
Chemotherapy-related adverse
events
28
Chemotherapy-related adverse
events
77
not shown
FLIC-score*
9
FLIC-score*
4,7
TCM-score*
-1
TCM-score*
0
Ovary IA–IC Iscador (21) Self-regulation
questionnaire, (score 1–6)
median difference
Ovary,
others
Inoperable
None (21)
Radiation,
cisplatin,
holoxan,
Helixor (23)
Radiation,
cisplatin,
holoxan (21)
Nausea ,
vomiting ,
depression of
leucopoiesis
0.005, 0.08,
0.003
KPS* 67% 76%
(p = 0.0008 II )
70% 74%
(p = 0.12 II )
Cervix IVA-B Iscador (19) Self-regulation
questionnaire, (score 1–6)
median difference
None (19)
Uterus IA-C Iscador (30) Self-regulation
questionnaire, (score 1–6)
median difference
None (30)
3.41 3.87 0.02 Grossarth
2001b [59]
KPS*
increase in %
of patients
50%
KPS*
increase in %
of patients
32%
FLIC 0.014
TCM 0.0007
KPS 0.002
Piao 2004
[56]
0.58 0.0002 0.30–0.90 Grossarth
2007a [50]
not shown Lange 1985
[63]
0.7 0.014 0.15–1.05 Grossarth
2007c [51]
0.4 0.0012 0.15–0.70 Grossarth
2008a [49]